A new study found that an HIV drug significantly reduces age-related inflammation and other signs of aging in mice. The findings were published in the journal Nature.
"This holds promise for treating age-associated disorders including Alzheimer's," said the senior author. "And not just Alzheimer's but many other diseases: Type 2 diabetes, Parkinson's, macular degeneration, arthritis, all of these different things. That's our goal." Age-related inflammation is an important component of age-associated disorders.
The HIV drug acts by halting retrotransposon activity in old cells. Retrotransposons -- DNA sequences able to replicate and move to other places -- make up a substantial fraction of the human genome. Retrotransposons are related to ancient retroviruses that, when left unchecked, can produce DNA copies of themselves that can insert in other parts of a cell's genome. Cells have evolved ways to keep these "jumping genes" under wraps, but as the cells age, the retrotransposons can escape this control, earlier research from the lab showed.
In the Nature paper, the research team showed that an important class of retrotransposons, called L1, escaped from cellular control and began to replicate in both senescent human cells -- old cells that no longer divide -- and old mice. Retrotransposon replication, specifically the DNA copies of L1, is detected by an antiviral immune response, called the interferon response, and ultimately triggers inflammation in neighboring cells, the researchers found.
These retrotransposons are present in every type of tissue, which makes them a compelling suspect for a unified component of cellular aging, the senior author said. Understanding that, the team uncovered the interferon response, the potential mechanism through which these jumping genes may cause cellular inflammation without necessarily causing damage to the genome.
"This interferon response was a complete game changer," the senior author said, noting that it is hard to track where newly inserted transposable elements may have inserted themselves in a genome that contains a vast number of inactive and active retrotransposon sequences.
The interferon-stimulating copies of L1 DNA require a specific protein called reverse transcriptase. HIV and other retroviruses also require reverse transcriptase proteins to replicate, the senior author said. In fact, AZT, the first drug developed to treat HIV/AIDS, halts HIV reverse transcriptase. Current multi-drug cocktails used to treat or prevent HIV/AIDS still contain specific reverse transcriptase inhibitors. The team thought that this class of drugs may keep the viral-like L1 retrotransposon from replicating and thereby prevent the inflammatory immune response.
The team tested six different HIV reverse transcriptase inhibitors to see if they could block L1 activity and the interferon response. One generic HIV drug, lamivudine, stood out because of its activity and low side effects.
Growing human cells in the presence of lamivudine did not impact when the cells reached senescence or kill the senescent cells, the senior author said. But lamivudine did decrease the interferon response and the late-stage senescence-associated secretory phenotype (SASP) -- the important characteristics of senescent cells that promote inflammation in their neighbors.
"When we started giving this HIV drug to mice, we noticed they had these amazing anti-inflammatory effects," the senior author said. "Our explanation is that although L1s are activated relatively late in senescence, the interferon response reinforces the SASP response and is responsible for age-associated inflammation."
Treating 26-month-old mice (roughly equivalent to 75-year-old humans) with lamivudine for as little as two weeks reduced evidence of both the interferon response and inflammation. Treating 20-month-old mice with lamivudine for six months also reduced signs of fat and muscle loss as well as kidney scarring.
The results were encouraging, the senior author said, but there's more work to be done.
"If we treat with lamivudine, we make a tangible dent in the interferon response and inflammation," the senior author said. "But it doesn't quite go back down to normal. We can fix part of the problem, but we don't actually understand the whole aging problem yet. The L1 reverse transcripts are at least an important part of this mess."
The senior author is eager to translate the findings to humans. Specifically, he would like begin clinical trials of lamivudine for various age-associated conditions such as frailty, Alzheimer's disease and arthritis. Lamivudine was approved by the Food and Drug Administration in 1995, has been used to treat HIV/AIDS for decades, and its pharmacological activity and safety are well established, the senior author said. The new clinical trials could be streamlined and focused on lamivudine's efficacy in treating age-associated disorders, the senior author added.
The senior author would also like to develop a new reverse transcriptase inhibitor specifically for the L1 reverse transcriptase. To aid in developing a specific therapeutic with minimal side effects, the molecular structure of the L1 reverse transcriptase needs to be determined. Researchers could also develop other types of drugs that target the L1 retrotransposons.
https://news.brown.edu/articles/2019/02/aging
https://www.nature.com/articles/s41586-018-0784-9
Latest News
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Mapping microbiome in metas…
By newseditor
Posted 22 Apr
Full-length mRNA packaged i…
By newseditor
Posted 22 Apr
Glucose-sensing mechanism t…
By newseditor
Posted 21 Apr
Other Top Stories
Immunotherapy against clotting factor to protect neuroinflammation…
Read more
How gene activity shapes immunity across species
Read more
Glutamine metabolism affects T cell signaling and function
Read more
Nature of immune cells in the human brain disclosed
Read more
Immune cells could hold key to therapies for spinal cord injuries
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Neuronal activity rapidly r…
By newseditor
Posted 22 Apr
A perspective on muscle phe…
By newseditor
Posted 22 Apr
Foxp1 suppresses cortical a…
By newseditor
Posted 22 Apr
Single-cell long-read seque…
By newseditor
Posted 22 Apr
Unlocking potential: the ro…
By newseditor
Posted 22 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar